Situation Report of COVID-19 by Sakura Alumni

Ooi Hong Kean

SARS−CoV−2 (COVID−19) has spread throughout the world and is still a pandemic today. Through the Sakura Science Program conducted by Azabu University, many veterinarians from various Asian countries and regions have been invited to visit Japan. We have formed an international network to share information on infectious diseases that are prevalent in our respective countries. Through this information sharing, we hope to contribute to the international control of infectious disease, in one way or another, as stated in our project slogan: Harmony, Fraternity and Networking through learning together and from each other. Through our international network and the principle of information sharing, we present the current COVID−19 situation in the various countries and regions as follows.

Advisor for International Relation and Cooperation, Sakura Science Program Headquarters,
Former Professor of Azabu University, Japan　Ooi Hong Kean, DVM, PhD,

Profile of Ooi Hong Kean

Born in 1956 in Malaysia. Came to Japan in 1975 under MEXT scholarship. Graduated from Hokkaido University (Japan) with a veterinary degree. After obtaining a Ph.D., he worked at Hokkaido Veterinary Center which was in the private sector. Later, appointed as an instructor at Hokkaido University. Moved to National Chung Hsing University (Taiwan), and served as Assoc.Professor, Professor and Dean of Office of International Affairs. Seconded to Yamaguchi University (Japan) to serve as Professor and Deputy Vice-President. From 2013 to 2021, served as a professor at Azabu University (Japan). Presently, being appointed as Advisor for International Relation and Cooperation at Sakura Science Program Headquarters, JST.
Specialty: Veterinary Parasitology, Zoonosis, Public Health, Laboratory Animal Science
has authored or co−authored more than 135 scientific papers.

Since 2014 to 2020, Prof. Ooi has been conducting the Sakura Science Exchange Program (SSP) project at Azabu University annually, with the theme related to the diagnosis and control of infectious diseases, especially zoonotic and epizootic diseases. The SSP participants came from different countries throughout Asia. After returning to their home countries, the SSP alumni of Azabu University formed an international scientific network to share information on the control of infectious diseases in their respective countries.

Situation Reports

covers newest report

Report on the Online International Conference on the New Coronavirus in Here.

Total number of COVID−19 cases and percentage of population vaccinated by countries/regions

As of Nov. 2, 2021

Country/Region	Population	Total COVID cases*	Total COVID deaths*	% of Population Vaccinated**	Type of Vaccine***
Argentina	44.4 million	5,289,945	115,989	75	Md, PfB, Can, Spk, AZ, Cv, SinoPh, SinoV
Bangladesh	163.6 million	1,569,753	27,870	25	Md, PfB, Spk, Jns, Cv, SinoPh, SinoV
Bhutan	0.7 million	2,621	3	75	Md, Cv
Brunei	0.4 million	13,246	89	80	Md, PfB, AZ, SinoPh
Cambodia	16.3 million	118,702	2,800	81	AZ, SinoPh, SinoV
Chile	19.3 million	1,696,786	37,777	86	PfB, Can, Spk, Jns, AZ, SinoV
China	1.4 billion	97,314	4,636	76	An, Can, SinoPh, SinoV, Minhai
India	1.2 billion	34,285,814	458,470	53	Zydus, Md, Spk, Jns, AZ, Cv, Bha
Indonesia	255 million	4,244,761	143,423	44	An, Md, PfB, Can, Spk, Jns, AZ, SinoPh, SinoV
Iran	85.4 million	5,934,495	126,456	61	Vax, Spk, Spk, Jns, AZ, SinoPh, Bha, Shifa
Kazakhstan	18.6 million	941,793	12,133	44	Spk, SinoV, QV
Republic of Korea	51.2 million	367,974	2,874	80	Md, PfB, Jns, AZ
Laos	6.4 million	40,956	67	44	Spk, SinoPh, SinoV
Malaysia	32 million	2,476,268	28,975	78	Md, PfB, Can, Jns, AZ, SinoPh, SinoV
Mongolia	3.2 million	361,388	1,755	68	Md, PfB, Spk, AZ, SinoPh
Myanmar	51.4 million	500,950	18,714	23	Spk, Cv
Nepal	28.7 million	813,011	11,416	29	Spk, Cv, Jns, SinoPh, SinoV, Bha
Pakistan	207.7 million	1,274,017	28,466	32	Md, PfB, Can, Spk, AZ, SinoPh, SinoV
Papua New Guinea	8.6 million	29,813	370	2	Jns, AZ, SinoPh
Peru	33.6 million	2,202,189	200,276	57	PfB, Jns, AZ, SinoPh
Philippines	100.9 million	2,790,375	43,276	25	Md, PfB, Spk, Jns, AZ, SinoPh, SinoV, Bha
Singapore	5.6 million	200,844	421	81	Md, PfB, SinoV
Sri Lanka	21.0 million	541,639	12,133	71	Md, PfB, Spk, AZ, Cv, SinoPh, SinoV
Taiwan	23.6 million	16,421	847	72	Medi, Md, PfB, AZ
Thailand	68.9 million	1,927,763	19,338	61	Md, PfB, Jns, AZ, SinoPh, SinoV
Uzbekistan	34.1 million	186,521	1,327	38	An, Spk, AZ
Vietnam	94.6 million	926,720	22,131	58	CIGB, Md, PfB, Spk, Jns, AZ, SinoPh
Japan	125.9 million	1,722,864	18,268	78	MdTak, PfB, AZ
World	7.9 billion	248,023,907	5,024,258	50	23 vaccines approved by at least 1 country

Source of data

* Total cases & death: Culminated figures since Jan. 2020
** % of total (fully+partially) population vaccinated with COVID−19 vaccines
*** Type of Vaccines

DNA vaccine

Zydus: Zydus Cadila, ZyCoV−D

Protein Subunit vaccine

An: Anhui Zhifei Longcom, ZF2001
Vax: Vaxine/CinnaGen Co., COVAX−19
Medi: Medigen, MVC−COV1901
CIGB: Center for Genetic Engineering & Biotechnology, CIGB−66

mRNA vaccine

Md: Moderna, mRNA−1273
MdTak: Takeda, TAK−919 (Moderna formulation)
PfB: Pfizer/BioNTech, BNT162b2

Non−Replicating Viral Vector

Can: CanSino, Ad5−nCoV
Spk: Gamaleya, Sputnik V or Sputnik Light
Jns: Janssen (Johnson & Johnson), Ad26.COV2.S
AZ: Oxford/AstraZeneca, AZD122
Cv: Serum Institute of India, Covishield (Oxford/AstraZeneca formulation)

Inactivated vaccine

SinoPh: Sinopharm BBIBP−CorV (Vero Cells), or Inactivated (Vero Cells)
SinoV: Sinovac, CoronaVac
Minhai: Minhai Biotechnology Co., SARS−CoV−2 Vaccine (Vero Cells)
Shifa: Shifa Pharmed Industrial Co., COVID−19 Inactivated Vaccine
Bha: Bharat Biotech, Covaxin
QV: Kazakhstan RIBSP, QazVac

Situation Report of COVID−19 by Sakura Alumni